Organic Active Ingredients TRIZ Cases

Imidazodiazepine compounds act as positive allosteric modulators on dopamine D1 receptors to enhance therapeutic efficacy.

Lyophilized beta-D-glucan and agarose form a porous matrix that conforms to resection voids, enabling accurate imaging marker visualization.

Compound 1 targets Nav1.8 sodium channels to treat acute and chronic pain while minimizing systemic side effects.

Increasing glutamine concentration to 12-80% of total protein improves cortical, subcortical, and white matter volumes in preterm infants.

Enzymatic hydrolysis and transesterification modify insect-extracted lipids to improve water dispersibility and reduce hardness at lower temperatures.

Segmented radioprotective kits with synergistic formulations provide immediate public access, reducing medical resource burden during radiation emergencies.

Aprotinin carrier protein moves therapeutic agents across the blood-brain barrier via receptor-mediated transcytosis.

A MEK1/2 inhibitor drives neural stem cell differentiation into functional neurons.

A pentaaza macrocyclic ring complex targets specific tumor biomarkers to enable effective cancer treatment.

Dimeric palladium(I) complexes with direct metal-metal bonds overcome hydrolysis instability to treat cisplatin-resistant tumors.

Lung administration of HMW-HA modulates the immune response to prevent cytokine storm, reducing organ damage and mortality in severe COVID-19 cases.

MGL inhibitors elevate endogenous 2-AG levels to provide analgesic effects without synthetic cannabinoid side effects.

Conjugating PMPC to nucleic acid aptamers extends blood half-life and avoids anti-PEG antibody production.

Pyrazolo[1,5-a]pyrimidine compounds treat Pneumovirinae infections by inhibiting viral replication.

Cyclic polyolefin inner layers prevent pharmaceutical sorption while conventional port materials reduce manufacturing costs.

A pharmaceutical composition combining an anti-TFPI antibody with cross-linked hyaluronic acid to inhibit coagulation and protect joint surfaces.

Novel macro-heterocyclic compounds with 17-25 membered rings inhibit hepatitis C virus protease activity.

PRMT5 inhibitors modulate antigen presentation to enhance antitumor immune responses in cancer therapy.

Competitive ALDH3A1 inhibitors prevent drug breakdown, restoring efficacy against resistant cancer cells.

Ester prodrugs of NMDA receptor modulators improve blood-brain barrier permeability to treat depression with reduced psychometric side effects.

Thiomorpholino antisense oligonucleotides induce dystrophin exon skipping with extended serum stability.

Rac1 inhibitors reduce airway hyperresponsiveness and resistance independently of anti-inflammatory effects, addressing severe asthma limitations.

Segmented inhibitor structures reduce pathological neutrophil activity and citrullination levels in rheumatoid arthritis.

Triazolopyridine derivatives resolve nausea and emesis side effects by achieving selective PDE4D inhibition via local quality design.

Segmented cartridges isolate moisture while rigid air conduits deagglomerate diketopiperazine microparticles for consistent dosing.

A nitrogen-containing metal complex achieves high tumor accumulation through specific heterocyclic ring structures.

Administering CD36-expressing fibroblasts shifts metabolism to reduce extracellular matrix accumulation in fibrotic diseases.

Benzopyranyl tetracycle compounds perturb post-translational modification of HMGB proteins to suppress inflammatory responses.

Formula I and II compounds inhibit Galectin-3 activity via beta-galactoside motifs, improving specificity for fibrotic disease treatment.

Tertiary amine piperazine lipids balance uptake and release, overcoming electrostatic binding that hinders intracellular nucleic acid delivery.

Replacing bulky peptidomimetics with compact aminodihydrothiazine scaffolds improves membrane permeability while maintaining inhibition potency.

A dioxane compound acts as a dual TNFR1 antagonist and TNFR2 agonist to modulate renal pathways.

N-butylidenephthalide delays Purkinje cell degeneration by activating adenosine A1 receptors, addressing ineffective treatments for spinocerebellar atrophy.

VE607 binds the spike protein receptor binding domain to block viral entry, reducing escape risk from variants.

Segmenting current across five channels resolves the contradiction between high amplitude requirements and skin safety risks.

Optimized arginine content and nitrogen substitution prevent precipitation and adverse effects in stable dexibuprofen injections.

Formula I compounds block CYP11B2 synthesis, preventing aldosterone breakthrough and organ damage from rebound effects.

Replacing benzyl benzoate with safer solvents improves dissolution rate while maintaining formulation stability.

Naphthyridone compounds inhibit RAF and Bcr-Abl kinases to overcome resistance mechanisms while reducing dose-limiting toxicities.

Native cohumulone in a delayed release capsule activates TAS2R40 receptors to reduce energy intake without causing nausea.

Antisense oligonucleotides bind conserved genomic RNA regions to inhibit viral replication.

Formula Ia compounds act as S1P1 receptor agonists to modulate leukocyte trafficking, resolving bradycardia risks associated with prior agents.

Oral synthetic mescaline administration attenuates substance intake by 20% or more, addressing limited FDA-approved treatments.

Carboxylic acid telmisartan derivatives treat non-alcoholic steatohepatitis by lowering liver triglycerides and fibrosis progression.

Acyl chloride protects the 4-N position of Gemcitabine, preventing metabolic deamination and reducing normal cell cytotoxicity.

Dendrogenin A resolves insufficient immune reprogramming by inducing tumor cell differentiation and enhancing antigen presentation.

Neoadjuvant antibody-drug conjugates overcome therapy resistance in refractory cancers by targeting Trop-2 with SN-38.

Beta-catenin and IDO inhibitors convert non-inflamed tumors into inflamed phenotypes, resolving tumor resistance to checkpoint blockade therapies.

A CaMKK2 inhibitor accelerates hematopoietic stem cell regeneration by modulating kinase activity.

Double-stranded ribonucleic acid triggers RNA interference to silence Hepatitis B viral genes, reducing viral burden and overcoming drug resistance.

A risperidone long-acting injectable depot composition achieves therapeutic plasma concentrations without oral supplementation.

Alstonine derivatives modulate serotonin receptors to address inadequate efficacy and seizure risks in current antipsychotic treatments.

Bile acid receptor agonists activate FXR and TGR5 receptors to modulate dopamine neurotransmission.

Optimized phospholipid and cholesterol ratios in the lipid particle composition improve bone marrow targeting capability for panobinostat delivery.

Phosphorothioate and boranophosphate modifications in the 5′-cap structure prevent decapping enzyme degradation, increasing RNA stability.

Freeze-drying dabigatran in acidic plasma creates stable calibrators that resolve compound instability and enable reliable pharmacodynamic monitoring.

PEG-based solvent systems form soluble micellar nanoaggregates to resolve low water solubility and inconsistent absorption of oral tetraiodothyronine.

Double-stranded RNA interference agents target the Serpina1 gene to reduce misfolded protein accumulation in liver disease treatment.

Hydroxypropyl starch replaces complex biological promoters to boost IgA levels, preventing infections and allergic reactions by blocking pathogen binding.

Spiro-linked rings and fluorine substitution on pyrazolone cores improve therapeutic efficacy and specificity while minimizing side effects.

A mouth ulcer treatment kit uses an adjustable nozzle sprayer to deliver a multi-ingredient pharmaceutical formulation directly to affected areas.

Stable lysine salt forms of 15-HETrE prevent fatty acid dimer formation at room temperature, ensuring storage stability without frozen conditions.

Ophthalmic composition with recoflavone and permeation enhancers overcomes corneal barrier limitations to improve dry eye treatment efficacy.

Hot high-pressure homogenization creates berbamine solid lipid nanoparticles without organic solvents, achieving high drug loading and bioavailability.

Hsp90 inhibitors modulate chemotherapy resistance by targeting heat shock protein interactions, improving patient outcomes.

Blocking the non-canonical TCA cycle via ATP citrate lyase inhibition prevents metabolic shifts that cause stem cells to exit the pluripotent state.

Formula I compounds modulate kinase activity via localized molecular features, resolving selectivity trade-offs to minimize off-target effects.

Low molecular weight gelators combined with gum Arabic provide hemostatic properties without skin stickiness.

Cationic peptide-linked morpholino antisense oligonucleotides penetrate muscle cells to neutralize toxic RNA.

Replacing inner ring methyl groups with halogens in thyroid hormone analogs increases binding affinity to the TR ligand binding domain.

Oxa acid emulsifiers form small micelles to boost bioavailability while avoiding toxicity from conventional surfactants.

Segmented solid dosage form delivers ondansetron via immediate and sustained layers, resolving frequent dosing conflicts.

Medium molecular weight heparin inhibits von Willebrand factor-dependent platelet aggregation, addressing microthrombosis in endotheliopathy.

Anti-CD112R antibodies block inhibitory signaling to enhance immune cell activation.

Crofelemer targets CFTR and calcium-activated chloride channels to resolve secretory diarrhea complications in congenital disorders.

Dimethyl acetamide dissolves lipophilic gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, maintaining stability for 48 hours despite poor water solubility.

Nasal nanoemulsion vaccines transport tumor antigens to lymph nodes, activating Toll-like receptors to reduce metastasis incidence.

Administering 2'-FL and LNnT oligosaccharides reduces full enteral feeding time by two days while supporting gut maturation.

Oral pentosan polysulfate sodium prevents recurrent urinary tract infection by blocking bacterial adhesion without causing drug resistance.

Segmented chewable amphetamine tablets with resin complexes deliver stable plasma levels over thirteen hours while enabling easy administration.

HBV RNAi triggers silence viral genes via sequence-specific antisense oligonucleotides, achieving complete remission without drug resistance.

A self-emulsifying omega-3 fatty acid composition uses optimized polysorbate and lecithin concentrations to form stable micelles for rapid dispersion.

Imidazopyrido pyrimidine compounds deliver strong inhibitory activity against cyclin-dependent kinases while maintaining improved pharmacokinetic properties.

Combining IAP inhibitors with PARP or MEK inhibitors overcomes cancer cell resistance by sensitizing cells to apoptosis and improving treatment outcomes.

HMGB1 antagonists block the TLR4/MD-2 signaling axis, resolving late mediator inflammation without impairing immune response.

Segmented lipoic acid pellets with pH-resistant coatings prevent polymerisation and maintain composition stability.

MeAIB inhibits the SNAT2 transporter to reduce blood pressure, addressing adverse effects of current antihypertensive drugs.

Specific mass ratios of diclofenac sodium, dimethyl sulfoxide, and citric acid suppress time-dependent crystallization while enhancing skin permeability.

R-enantiomer etomidate derivatives reduce 11β-hydroxylase inhibition to accelerate post-operative recovery.

Polymer blend stabilizes amorphous NSAID in solidified melt extrudate, ensuring consistent rapid drug release without additional dissolution aids.

Liposomal nanoparticles deliver CD47-targeting mRNA to inhibit nucleic acid metabolism, inducing apoptosis while sparing normal cells.

Human milk oligosaccharides increase bifidobacteria abundance to treat prolonged fatigue unresponsive to rest.

GRP inhibitors block the GRP-GRPR pathway to mitigate lung damage and lethality caused by excessive inflammatory responses.

Targeting the conserved E6AP host factor with dsRNA achieves broad-spectrum efficacy against diverse high-risk HPV subtypes.

Topical detomidine formulations create a skin depot that gradually releases the active ingredient to provide localized analgesia.

Escalating CD19xCD3 dosing reduces toxicity while treating relapsed Burkitt lymphoma.

Benzylthiophene derivatives inhibit STAT3 phosphorylation, bypassing failed dimerization strategies to treat cancer.